X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (213) 213
female (98) 98
male (98) 98
urology & nephrology (91) 91
risk factors (81) 81
mortality (79) 79
middle aged (78) 78
kidney diseases (76) 76
medicine, general & internal (73) 73
aged (72) 72
diabetes (61) 61
abridged index medicus (60) 60
treatment outcome (59) 59
cardiovascular diseases (57) 57
chronic kidney disease (57) 57
clinical trials (52) 52
randomized controlled trials as topic (52) 52
blood pressure (48) 48
cardiovascular disease (48) 48
cardiovascular diseases - prevention & control (47) 47
glomerular filtration rate (46) 46
diabetes mellitus (45) 45
risk (43) 43
outcomes (41) 41
endocrinology & metabolism (39) 39
diabetes mellitus, type 2 - drug therapy (38) 38
hypertension (37) 37
type 2 diabetes (37) 37
albuminuria (36) 36
meta-analysis (34) 34
nephrology (34) 34
blood-pressure (33) 33
chronic kidney failure (31) 31
chronic kidney-disease (31) 31
diabetes mellitus, type 2 - complications (31) 31
drug therapy (31) 31
research (31) 31
adult (30) 30
double-blind method (30) 30
hemodialysis (29) 29
analysis (28) 28
cardiovascular diseases - mortality (28) 28
disease (28) 28
antihypertensive agents - therapeutic use (27) 27
peripheral vascular disease (27) 27
canagliflozin (25) 25
cardiac & cardiovascular systems (25) 25
disease progression (25) 25
hypertension - drug therapy (25) 25
stage renal-disease (25) 25
stroke (25) 25
empagliflozin (24) 24
kidney-disease (24) 24
kidneys (24) 24
care and treatment (23) 23
glomerular-filtration-rate (23) 23
nephropathy (23) 23
progression (23) 23
health aspects (22) 22
hemodialysis-patients (22) 22
kidney failure, chronic - therapy (22) 22
renal dialysis (22) 22
double-blind (21) 21
internal medicine (21) 21
risk assessment (21) 21
epidermal growth factor receptors (20) 20
hypoglycemic agents - therapeutic use (20) 20
patients (20) 20
kidney transplantation (19) 19
prevalence (19) 19
blood pressure - drug effects (18) 18
cardiovascular diseases - etiology (18) 18
cardiovascular events (18) 18
cardiovascular-disease (18) 18
follow-up studies (18) 18
metaanalysis (18) 18
renal insufficiency, chronic - complications (18) 18
studies (18) 18
systematic review (18) 18
heart failure (17) 17
myocardial infarction (17) 17
placebo-controlled trial (17) 17
safety (17) 17
creatinine (16) 16
dialysis (16) 16
kidney disease (16) 16
medical research (16) 16
risk-factors (16) 16
complications and side effects (15) 15
end-stage renal disease (15) 15
kidney failure, chronic - complications (15) 15
prevention (15) 15
prognosis (15) 15
cause of death (14) 14
clinical medicine (14) 14
cohort studies (14) 14
diabetes mellitus, type 2 (14) 14
efficacy (14) 14
kidney (14) 14
mellitus (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 22, pp. 2175 - 2178
Blood pressure is a potent determinant of cardiovascular risk, but the most appropriate targets for blood-pressure lowering have long been debated.... 
HYPERTENSION | MEDICINE, GENERAL & INTERNAL | RISK | Blood Pressure | Humans | Antihypertensive Agents - administration & dosage | Female | Hypertension - drug therapy | Male | Practice Guidelines as Topic | Clinical trials | Usage | Blood pressure | Regulation | Health aspects | Cardiovascular disease | Diabetes | Cardiovascular diseases
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10017, pp. 435 - 443
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 21, p. 2099
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 7, pp. 644 - 657
In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor... 
METAANALYSIS | ATRIAL-NATRIURETIC-PEPTIDE | RATIONALE | INTENSIVE GLUCOSE CONTROL | PLACEBO-CONTROLLED TRIAL | OUTCOMES | INHIBITORS | STAGE KIDNEY-DISEASE | PROGRESSION | BASE-LINE CHARACTERISTICS | MEDICINE, GENERAL & INTERNAL | DESIGN | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Kidney Diseases - mortality | Male | Canagliflozin - adverse effects | Disease Progression | Foot - surgery | Glomerular Filtration Rate - drug effects | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Amputation - statistics & numerical data | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Heart | Complications and side effects | Care and treatment | Abnormalities | Amputation | Myocardial infarction | Heart attacks | Body weight | Clinical trials | Cardiovascular disease | Blood pressure | Drug dosages | Heart failure | Cerebral infarction | Stroke | Statistical analysis | Kidneys | Metatarsal | Diabetes mellitus | Toe | FDA approval | Glomerular filtration rate | Medicine | Studies | Side effects | Sodium | Diabetes | Kidney diseases | Cardiovascular diseases | Health risk assessment | Kidney transplantation
Journal Article
by Levin, Adeera and Tonelli, Marcello and Bonventre, Joseph and Coresh, Josef and Donner, Jo-Ann and Fogo, Agnes B and Fox, Caroline S and Gansevoort, Ron T and Heerspink, Hiddo J L and Jardine, Meg and Kasiske, Bertram and Köttgen, Anna and Kretzler, Matthias and Levey, Andrew S and Luyckx, Valerie A and Mehta, Ravindra and Moe, Orson and Obrador, Gregorio and Pannu, Neesh and Parikh, Chirag R and Perkovic, Vlado and Pollock, Carol and Stenvinkel, Peter and Tuttle, Katherine R and Wheeler, David C and Eckardt, Kai-Uwe and Adu, Dwomoa and Agarwal, Sanjay Kumar and Alrukhaimi, Mona and Anders, Hans-Joachim and Ashuntantang, Gloria and Basnet, Shakti and Bello, Aminu K and Chailimpamontree, Worawon and Correa-Rotter, Ricardo and Craig, Jonathan and Douthat, Walter G and Feldman, Harold I and Ganji, Mohammad Reza and Garcia-Garcia, Guillermo and Gharbi, Mohammed Benghanem and Harris, David C and Jha, Vivekanand and Johnson, David W and Kazancioglu, Rumeyza and Langham, Robyn and Liu, Zhi-Hong and Massy, Ziad A and Nangaku, Masaomi and Nelson, Robert G and O'Donoghue, Donal and Okpechi, Ikechi and Pecoits-Filho, Roberto and Powe, Neil R and Remuzzi, Giuseppe and Roberts, Charlotte and Rossert, Jerome and Sola, Laura and Stengel, Benedicte and M, Ernest K. Sumaili and Suzuki, Yusuke and Tanaka, Tetsuhiro and Tatiyanupanwong, Sajja and Thomas, Bernadette and Uhlig, Katrin and Walker, Robert and White, Sarah L and Wiecek, Andrzej and Yang, Chih-Wei and ISN Global Kidney Health Summit participants and ISN Global Kidney Hlth Summit
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10105, pp. 1888 - 1917
Journal Article